Search clinical trials for: Myeloproliferative disorder (MPD) with eosinophilia

Total 252831 results

Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Active, not recruiting

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera

Australia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
Celgene

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Eosinophilic Esophagitis

Australia, United States, Argentina, Austria, Belgium, Canada, Germany, Israel, Italy, Japan, Poland, Portugal, Spain, Switzerland, United Kingdom
AstraZeneca

Completed

Change in Patient-Reported Outcomes in Severe Eosinophilic Asthma Patients Treated With Benralizumab Under Real-life Conditions (imPROve)

Asthma

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis

Myelofibrosis

United States
Protagonist Therapeutics, Inc.

Enrolling by invitation

Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera (THRIVE)

Polycythemia Vera

United States
McMaster University
Teva Canada

Completed

Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma

Asthma; Eosinophilic

Canada
RWTH Aachen University
Novartis Pharmaceuticals

Active, not recruiting

The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia (Ruxo-BEAT)

Polycythemia Vera (PV) | Essential Thrombocythemia (ET)

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Therapy-Related Acute Myeloid Leukemia and other conditions

United States
St. Jude Children's Research Hospital

Active, not recruiting

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

Hodgkin Lymphoma | Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Chronic Myeloid Leukemia (CML) | NK-Cell Leukemia | Non Hodgkin Lymphoma (NHL) | Juvenile Myelomonocytic Leukemia (JMML)

United States
Allakos Inc.

Completed

A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis (ENIGMA)

Eosinophilic Gastritis | Eosinophilic Gastroenteritis

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Suspended

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | Recurrent Acute Lymphoblastic... and other conditions

United States
Novartis Pharmaceuticals

Completed

Real-world Effectiveness of Asciminib and Treatment Patterns in Patients With Chronic Myeloid Leukemia With T315I Mutation - a Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)

Chronic Myeloid Leukemia With T315I Mutation

Switzerland
Ellodi Pharmaceuticals, LP

Available

Expanded Access Protocol for Patients With Eosinophilic Esophagitis

Eosinophilic Esophagitis

United States
Celgene

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis

Eosinophilic Gastroenteritis

Japan
Imago BioSciences, Inc., a subsidiary of Merck...

Completed

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

Myelofibrosis | Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis (PPV-MF) | Post-essential Thrombocythemia Myelofibrosis (PET-MF)

Germany, United States, Australia, Italy, United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Hodgkin Lymphoma | Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Acute Leukemia | Myelodysplastic Syndrome | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Myeloproliferative... and other conditions

United States
University of Utah
National Cancer Institute (NCI)

Terminated

CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia

Obstructive Sleep Apnea Syndrome | Polycythemia Vera | Essential Thrombocythemia | CALR Gene Mutation | JAK2 Gene Mutation | MPL Gene Mutation

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic... and other conditions

United States
Fred Hutchinson Cancer Center

Active, not recruiting

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Follicular Lymphoma | Acute Myeloid Leukemia | Myelofibrosis | Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma and other conditions

United States
Allakos Inc.

Completed

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis (EoDyssey)

Eosinophilic Gastroenteritis | Eosinophilic Duodenitis

United States
Allakos Inc.

Completed

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis (KRYPTOS)

Eosinophilic Esophagitis

United States, Australia, Netherlands
Fundacion CRIS de Investigación para Vencer el...
Apices Soluciones S.L.; Incyte Biosciences UK

Active, not recruiting

Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP) (ResToP)

Chronic Myeloid Leukemia, Chronic Phase

Spain
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

United States
John Mascarenhas
National Cancer Institute (NCI); National Institutes of Health (NIH); Celgene... and other collaborators

Completed

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

IDH2 Mutation | Accelerated/Blast-phase Myeloproliferative Neoplasm | Chronic-phase Myelofibrosis

United States, Canada
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Completed

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Polycythemia Vera | Myelofibrosis | Leukemia, Myelomonocytic, Chronic | Hypereosinophilic Syndrome | Mastocytosis | Agnogenic Myeloid Metaplasia

United States
Washington University School of Medicine
Rigel Pharmaceuticals

Terminated

Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

Myelofibrosis | Thrombocytopenia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Hodgkin Lymphoma | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Recurrent Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
Naoyuki G. Saito, M.D., Ph.D.

Withdrawn

A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Acute Lymphocytic Leukemia

United States
AbbVie

Completed

A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review (METER)

Myelofibrosis

Argentina, Australia, Brazil, Canada, Colombia, Greece, Italy, Mexico, Poland, Portugal, Romania, Taiwan, Turkey, United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

Hematopoietic and Lymphoid Cell Neoplasm | Myelofibrosis | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic Leukemia | High Risk... and other conditions

United States
AUSL Romagna Rimini

Completed

PREVALENCE STUDY OF PNH CLONES IN PATIENTS WITH NEOPLASIES

Myeloproliferative Neoplasm

Italy
University of Campinas, Brazil

Active, not recruiting

Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response (EDI-PIO)

Leukemia, Chronic Myeloid

Brazil
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Completed

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Canada
PharmaEssentia
Medpace, Inc.; EPS International; Brightech International

Active, not recruiting

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance (SURPASS ET)

Essential Thrombocythemia

United States, Canada, Korea, Republic of, China, Hong Kong, Singapore, Taiwan, Japan
City of Hope Medical Center

Terminated

Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
University of Auckland, New Zealand
Leukaemia & Blood Cancer New Zealand

Active, not recruiting

KISS Study: Kinase Inhibition With Sprycel Start up (KISS)

Chronic Myeloid Leukemia

New Zealand
Novartis Pharmaceuticals

Completed

Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database

Chronic Myeloid Leukemia

United States
Robert Lowsky
National Cancer Institute (NCI)

Completed

Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies

Recurrent Adult Acute Myeloid Leukemia | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Immunoblastic Large... and other conditions

United States
AstraZeneca

Terminated

A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid. (FJORD)

Bullous Pemphigoid

France, Italy, Spain, Germany, United States, Australia, China, Bulgaria, Israel, Japan, Greece
AstraZeneca

Terminated

A Study of Benralizumab in Patients With Eosinophilic Esophagitis (MESSINA)

Eosinophilic Esophagitis

United States, Italy, Spain, Canada, Poland, Germany, Japan, Netherlands, France, Israel, Russian Federation, United Kingdom
Protagonist Therapeutics, Inc.

Active, not recruiting

Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)

Polycythemia Vera

United States, India
M.D. Anderson Cancer Center

Completed

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Acute Lymphoblastic... and other conditions

United States
EsoCap AG
FGK Clinical Research GmbH; FGK Representative Service B.V.

Completed

A Study to Investigate the Efficacy and Tolerability of ESO-101 in Patients With Eosinophilic Esophagitis

Eosinophilic Esophagitis

Spain, Switzerland, Netherlands, Germany, Poland
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis

Myelofibrosis

China
Celgene

Active, not recruiting

A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Primary Myelofibrosis

Japan
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Juvenile Myelomonocytic Leukemia | Neurofibromatosis Type 1

United States
Washington University School of Medicine
BioLineRx, Ltd.

Completed

Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

Multiple Myeloma | Hodgkin Disease | Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myeloproliferative Neoplasm | Hodgkin's Disease | Hodgkins Disease

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Erythroid Leukemia | Acute Megakaryoblastic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Blast Phase Chronic Myelogenous Leukemia,... and other conditions

United States
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.

Myelofibrosis

China

Search clinical trials for: Myeloproliferative disorder (MPD) with eosinophilia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations